Drug politics--economic view-point of a practitioner
Băicuş, C.; Chivu, R.
Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 108(3): 674-678
2004
ISSN/ISBN: 0048-7848 PMID: 15832997 Document Number: 570572
Any expenditure made in a domain leads to the diminution of the expenditures in another domain. The list of reimbursed drugs should be decided after a cost effectiveness analysis. The treatments considered too expensive in the developed countries are even more expensive for a country like Romania. The practice guidelines do not consider the economic analysis of the treatments. As soon as the results of a study are statistically significant, the specialty societies include that drug into their guidelines. A treatment is more cost effective when the risk is higher, therefore the reimbursement should have to be done function of risk, too.